<DOC>
	<DOCNO>NCT02428036</DOCNO>
	<brief_summary>The purpose study determine whether TBI-1401 ( HF10 ) , spontaneously attenuate mutant Herpes Simplex Virus Type 1 ( HSV-1 ) , safe tolerable treatment solid tumor superficial lesion .</brief_summary>
	<brief_title>A Study TBI-1401 ( HF10 ) Patients With Solid Tumors With Superficial Lesions</brief_title>
	<detailed_description>This open label , non-randomized , dose escalation Phase I study evaluate repeat intratumoral administration TBI-1401 ( HF10 ) , spontaneously attenuate mutant HSV-1 , patient solid tumor superficial lesion ( e.g. , malignant melanoma squamous cell carcinoma skin ) . The study evaluate safety tolerability repeat intratumoral administration TBI-1401 ( HF10 ) dose level 1 x 10^6 TCID50/dose ( cohort 1 ) 1 x 10^7 TCID50/dose ( cohort 2 ) Japanese patient . Three patient enrol cohort . Patients cohort receive total four intratumoral administration lesion .</detailed_description>
	<criteria>Patients must histologically confirm solid tumor superficial lesion . Patients must unresectable standard therapiesresistant solid tumor . Patients must ≥ 20 year age . Patients must life expectancy ≥ 12 week . Patients must measurable nonvisceral lesion ( ) evaluable mWHO response criterion . Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Patients must adequate key organ function ( bone marrow , heart , lung , liver , renal , etc ) , define Absolute neutrophil count ≥ 1,500/μL . Platelet count ≥ 100,000/μL . Total bilirubin level ≤ 1.5 x upper limit normal ( ULN ) . AST/ALT level ≤ 2.5 x ULN , ≤ 5 x ULN liver metastases present . creatinine ≤ 1.5 x ULN . creatinine clearance ( calculate ) ≥ 60 mL/min/1.73 m^2 patient creatinine &gt; 1.5 x ULN . Patients must pass 4 week completion prior therapy [ except bone metastasis therapy ] , pass 8 week immuno checkpoint inhibitor treat . Patients must able understand willing sign write informed consent document . Patients history significant tumor bleeding , coagulation bleeding disorder . Patients Grade 2 adverse event Grade 2 great , except alopecia , result anticancer agent administer 4 week prior TBI1401 ( HF10 ) administration . Patients receive antiherpes medication [ except local treatment ointment ] . Patients receive steroid immunosuppressive agent [ except inhaled steroid ] . Patients clinically evident Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) Hepatitis C virus ( HCV ) infection . Patients receive antiplatelet medication . Patients receive anticoagulation medication . Patients presence medical history central nervous system metastasis . Patients Grade ≥ 2 preexist neurologic abnormality ( CTCAE version 4.0 ) . Patients severe cardiac disorder abnormal cardiac rhythm . Patients psychiatric disorder drug dependency affect informed consent . Pregnant breastfeeding woman ; woman men , normal reproductive potential , disagree protection pregnancy within timeframe study . Patients receive investigational product within 4 week , within 8 week immuno checkpoint inhibitor treat . Patients would limit compliance study requirement , determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>TBI-1401 ( HF10 )</keyword>
	<keyword>HF10</keyword>
	<keyword>HSV-1</keyword>
	<keyword>Oncolytic virus</keyword>
	<keyword>Oncolytic virotherapy</keyword>
	<keyword>Phase I</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Intratumoral administration</keyword>
</DOC>